Medical Insights from Industry

RSS

"Insights from Industry" is a dynamic series of interviews at the cutting edge of the medical industry. Every interviewee is a leader in their particular field and is handpicked to give an informative and accessible insight into their chosen field. These interviews are guaranteed to keep you in the know in a rapidly changing industry.

Continuous glucose monitoring in children: an interview with Terrance Gregg, CEO of Dexcom

Scientific research into CGM-like sensors goes back more than 40 years. I was working with the first company to begin commercial development, MiniMed, back in 1992 when the science was really beginning to percolate. In 1999 the FDA approved the first CGM device for use in the United States.

6 Apr 2014

Safer sharps: an interview with Paul Lindsell, Managing Director, MindMetre

In 2010, the European Council described sharps injuries as one of the most serious health and safety threats in European workplaces as an estimated one million injuries were occurring each year.

1 Apr 2014

Ulcerative colitis control: an interview with Dr Paul Robinson, Medical Director, MSD UK

Ulcerative colitis (UC) is an inflammatory bowel disease (IBD), which means there is chronic inflammation and ulceration in the lining of the digestive tract, usually in the large intestine.

26 Mar 2014

Endogenous tissue growth: an interview with Laurent Grandidier, CEO, Xeltis

ETG or Endogenous Tissue Growth is a new therapeutic category in which surgeons use implants designed to allow the body to repair itself by spontaneously growing natural, healthy tissue from the inside without the use of stem cells or animal-derived products.

25 Mar 2014

Real-time cervical cancer diagnostics: an interview with Sameer Kothari, Chief Executive of Zilico

Cervical cancer diagnosis is a two-step process. In developed countries, women are invited for a smear test which mainly uses LBC (liquid-based cytology), where a sample of cells are taken from the cervix and sent to a cytopathology lab for analysis.

From Zilico 19 Mar 2014

Non-alcoholic steatohepatitis (NASH): an interview with Jean-François Mouney, CEO of Genfit

The progressive form of Non-Alcoholic Fatty Liver Disease (NAFLD) is Non-Alcoholic Steatohepatitis (NASH), which defines a subgroup of NAFLD where liver steatosis co-exists with cell injury (hepatocyte ballooning) and inflammation with or without fibrosis at histological examination.

18 Mar 2014

Rheumatoid arthritis and switching TNFis: an interview with Professor Paul Emery, University of Leeds

Tumor necrosis factor inhibitors (TNFis) are used to treat inflammatory conditions, such as RA. These agents work by blocking TNF, an important mediator of inflammation in RA, in order to help reduce inflammation and stop disease progression.

12 Mar 2014

Homologous recombination technology for research applications in genetically modified rodents: an interview with Alexandre Fraichard, CEO, genOway

Homologous recombination is a technology that enables the targeted insertion of nucleotide fragments into the genome of a cell. It is called ‘homologous’ because it uses a sequence that is a homologue to the sequence being targeted in a gene, so that the sequence is recognized.

10 Mar 2014

UK waiting times for RA and PsA patients: an interview with Dr Marwan Bukhari, Consultant Rheumatologist at the University Hospitals of Morecambe Bay NHS Foundation Trust

Research shows that in cases of inflammatory joint disease, the earlier you catch the disease and suppress the immune system, the less likely a patient is to develop damaging and ongoing, chronic inflammation.

10 Mar 2014

Treating cystic fibrosis: an interview with Simon Bedson, Senior Vice President and International General Manager at Vertex

Cystic fibrosis is a rare, life-shortening genetic disease for which there is no cure. It affects more than 75,000 people worldwide. In CF, thick, sticky mucus blocks the passages in many organs, leading to a variety of symptoms. In particular, mucus builds up and clogs airways in the lungs making it easier for bacteria to grow.

5 Mar 2014

Advanced melanoma treatments: an interview with Dr. James Larkin, Consultant Medical Oncologist, The Royal Marsden

Advanced melanoma affects around 2,000 people per year in the UK. Advanced melanoma describes a melanoma that has spread from its site of origin to other areas of the body.

22 Jan 2014

Erosive GERD treatments: an interview with Professor Joaquim Moraes-Filho, University of São Paulo Medical School

Gastroesophageal Reflux Disease (GERD) is a condition that develops when the reflux of stomach contents causes troublesome symptoms and/or complications.

20 Jan 2014

Idiopathic pulmonary fibrosis (IPF) and herpesvirus saimiri: an interview with Elazar Rabbani, Chief Executive Officer of Enzo

Pulmonary fibrosis is a condition where fibrotic or scarred tissue progressively develops in the lungs. In some cases the particular cause is known but in others it remains unknown and is given the term “idiopathic”.

14 Jan 2014

New tools for neglected diseases: an interview with Dr. BT Slingsby, CEO, GHIT Fund

Nearly 3.3 billion people, a little less than half of our world’s population, are at risk of malaria, TB and what we call “neglected tropical diseases”—diseases caused by worms, parasites, viruses and bacteria like Chagas disease, river blindness, elephantiasis, sleeping sickness, etc.

24 Dec 2013

Reflux disease diagnosis: an interview with Professor Peter Dettmar, Managing Director of RD Biomed Limited

Generally speaking, reflux has been a major chronic issue for probably the last 40 or 50 years. When you look at the global population, depending on which country we're talking about, around 20% to 40% of individuals have reflux disease within their populations.

23 Dec 2013

Stem cell technology: an interview with Professor Igor Slukvin, University of Wisconsin-Madison and scientific founder of CDI and Cynata

Stem cells have a potential to develop into multiple cell types and divide without limit to replenish cells in human body throughout the life of individual.

16 Dec 2013

Circulating nucleosomes and colorectal cancer diagnostics: an interview with Dr. Stefan Holdenrieder, University Hospital Bonn

For my MD thesis I modified and evaluated an immunological assay that detected the cell death products “nucleosomes” as a new blood-based cancer biomarker. As cell death processes are enhanced or suppressed during different stages of tumor development, it was assumed that they may enable stage-dependent detection of cancer disease.

12 Dec 2013

Biosimulation and epilepsy treatments: an interview with Dr. Serge Bischoff, CEO of Rhenovia and RHENEPI program director

The need for biosimulation is primarily to do with the very high attrition rate in drug development and especially in the development of drugs for the central nervous system.

10 Dec 2013

‘Flesh-eating’ disease treatments: an interview with Dr. John Crew, Seton Medical Center

Untreated, the mortality probably exceeds 70%. Flesh eating is a description of Toxic Inflammatory Cellulitis which usually starts by bacterial subcutaneous infection followed by freezing in phase II healing which is inflammatory.

9 Dec 2013

Type 2 diabetes management: an interview with Professor Klaus Dugi, Corporate Senior Vice President Medicine, Boehringer Ingelheim

The rate of Type 2 Diabetes is rapidly increasing, particularly in Asian countries which make up more than 60 percent of the world’s diabetes population. So it’s really important physicians feel confident managing this chronic condition in their daily clinical practice.

5 Dec 2013